S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease
Makda Getachew Zewde,George Morales,Isha Gandhi,Umut Ozbek,Paibel Aguayo-Hiraldo,Francis Ayuk,Janna Baez,Chantiya Chanswangphuwana,Hannah Choe,Zachariah DeFilipp,Aaron Etra,Stephan A. Grupp,Elizabeth O. Hexner,William J. Hogan,Nora Rebeka Javorniczky,Stelios Kasikis,Carrie L. Kitko,Steven Kowalyk,Elisabeth Meedt,Pietro Merli,Ryotaro Nakamura,Muna Qayed,Ran Reshef,Wolf Rösler,Tal Schechter,Daniela Weber,Matthias Wölfl,Gregory A. Yanik,Rachel Young,John E. Levine,James L.M. Ferrara,Yi-Bin Chen +31 more
TL;DR: In this article, the utility of elafin as a prognostic biomarker in the general population of acute graft-versus-host disease patients undergoing hematopoietic cell transplantation (HCT) for hematologic malignancies was evaluated.
Journal ArticleDOI
KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy
Adam J. Lamble,Regina M. Myers,Agne Taraseviciute,Samuel John,Bonnie Yates,Seth M. Steinberg,Jennifer Sheppard,Alexandra E. Kovach,Brent L. Wood,Michael J. Borowitz,Maryalice Stetler-Stevenson,Constance M. Yuan,Vinodh Pillai,Toni Foley,Perry Chung,Lee Chen,Daniel W. Lee,Colleen Annesley,Amanda M. DiNofia,Stephan A. Grupp,Michael R. Verneris,Lia Gore,Theodore W. Laetsch,Deepa Bhojwani,Patrick A. Brown,Michael A. Pulsipher,Susan R. Rheingold,Rebecca Gardner,Nirali N. Shah +28 more
Journal ArticleDOI
Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial.
Stephan A. Grupp,Selim Corbacioglu,Takanori Teshima,Seong Lin Khaw,Franco Locatelli,Johan Maertens,Matthias Stelljes,Polina Stepensky,Paty Lopez,Vian Amber,Antonio Pagliuca,Paul G. Richardson,Mohamad Mohty +12 more
TL;DR: In this paper , the authors compared defibrotide prophylaxis plus best supportive care (BSC) versus best supportive Care alone for sinusoidal obstruction syndrome prevention after haematopoietic stem-cell transplantation (HSCT).
Journal ArticleDOI
CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity
Andrew M. Stein,Stephan A. Grupp,Stephan A. Grupp,John E. Levine,John E. Levine,Theodore W. Laetsch,Michael A. Pulsipher,Michael Boyer,Keith J. August,Bruce L. Levine,Carl H. June,Lori Tomassian,Sweta Shah,Mimi Leung,Pai-Hsi Huang,Sebastien Jolivet,Rakesh Awasthi,Karen Thudium Mueller,Patricia A. Wood,Shannon L. Maude,Shannon L. Maude +20 more
TL;DR: Pts with r/r ALL with higher peak transgene levels were more likely to develop Grade 3 and 4 CRS based upon both NCA and modeling of cellular kinetics, resulting in the higher Cmax among patients receiving tocilizumab.
Journal ArticleDOI
High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada
Sumit Gupta,Sarah Alexander,Sue Zupanec,Uma H. Athale,Mylene Bassal,Ethan Edwards,Paul Gibson,Donna L. Johnston,Stacey Marjerrison,Alexander Zorzi,Johann K. Hitzler,Ahmed Naqvi,Angela Punnett,James A. Whitlock,Stephan A. Grupp,Shannon L. Maude,Joerg Krueger +16 more
TL;DR: Traditional high-intensity chemotherapy for relapsed ALL that aims to minimize disease burden but carries significant morbidity may not be the best option for pre-CAR-T populations, as demonstrated in a population-based cohort of heavily pre-treated and high-risk patients.